Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Marie, Y.
Right arrow Articles by Delattre, J. -Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Marie, Y.
Right arrow Articles by Delattre, J. -Y.
NEUROLOGY 2005;64:1444-1445
© 2005 American Academy of Neurology
Brief Communications

EGFR tyrosine kinase domain mutations in human gliomas

Y. Marie, MSc, A. F. Carpentier, MD, PhD, A.M.P. Omuro, MD, M. Sanson, MD, PhD, J. Thillet, PhD, K. Hoang-Xuan, MD, PhD and J. -Y. Delattre, MD

From Department of Neurology Mazarin and Institut National de la Santé et de la Recherche Médicale (INSERM) UMR-495 (Y. Marie, and Drs. Carpentier, Sanson, Thillet, Hoang-Xuan, and Delattre), Hôpital de la Pitié-Salpêtrière, Paris, France; and Department of Neurology (Dr. Omuro), Memorial Sloan-Kettering Cancer Center, New York, NY.

Address correspondence and reprint requests to Dr. A Carpentier, Service de Neurologie Mazarin, Hôpital de la Pitié-Salpêtrière, 47 bd de l’Hopital, Paris, France; e-mail: antoine.carpentier{at}psl.ap-hop-paris.fr

Gefitinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor effective in patients with lung cancer with mutations in exons 19 and 21 of the EGFR tyrosine kinase domain. In this study, the authors tested the presence of such mutations in 95 gliomas including glioblastomas, anaplastic oligodendrogliomas, and low-grade gliomas. No mutation was found, which suggests that the biology of EGFR in gliomas is different from lung cancer and that this may be a factor in the resistance of glioblastomas to gefitinib.

Additional material related to this article can be found on the Neurology Web site. Go to www.neurology.org and scroll down the Table of Contents for the April 26 issue to find the title link for this article.

Received October 28, 2004. Accepted in final form December 10, 2004.




This article has been cited by other articles:


Home page
 Ann OncolHome page
B. Neyns, J. Sadones, E. Joosens, F. Bouttens, L. Verbeke, J.-F. Baurain, L. D'Hondt, T. Strauven, C. Chaskis, P. In't Veld, et al.
Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma
Ann. Onc., June 2, 2009; (2009) mdp032v1.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J.-S. Guillamo, S. de Bouard, S. Valable, L. Marteau, P. Leuraud, Y. Marie, M.-F. Poupon, J.-J. Parienti, E. Raymond, and M. Peschanski
Molecular Mechanisms Underlying Effects of Epidermal Growth Factor Receptor Inhibition on Invasion, Proliferation, and Angiogenesis in Experimental Glioma
Clin. Cancer Res., June 1, 2009; 15(11): 3697 - 3704.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. J. van den Bent, A. A. Brandes, R. Rampling, M. C.M. Kouwenhoven, J. M. Kros, A. F. Carpentier, P. M. Clement, M. Frenay, M. Campone, J.-F. Baurain, et al.
Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034
J. Clin. Oncol., March 10, 2009; 27(8): 1268 - 1274.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Broniscer, S. J. Baker, C. F. Stewart, T. E. Merchant, F. H. Laningham, P. Schaiquevich, M. Kocak, E. B. Morris, R. Endersby, D. W. Ellison, et al.
Phase I and Pharmacokinetic Studies of Erlotinib Administered Concurrently with Radiotherapy for Children, Adolescents, and Young Adults with High-Grade Glioma
Clin. Cancer Res., January 15, 2009; 15(2): 701 - 707.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. A. Brandes, E. Franceschi, A. Tosoni, M. E. Hegi, and R. Stupp
Epidermal Growth Factor Receptor Inhibitors in Neuro-oncology: Hopes and Disappointments
Clin. Cancer Res., February 15, 2008; 14(4): 957 - 960.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
S. Wang, P. Guo, X. Wang, Q. Zhou, and J. M. Gallo
Preclinical pharmacokinetic/pharmacodynamic models of gefitinib and the design of equivalent dosing regimens in EGFR wild-type and mutant tumor models
Mol. Cancer Ther., February 1, 2008; 7(2): 407 - 417.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
A. M.P. Omuro, S. Faivre, and E. Raymond
Lessons learned in the development of targeted therapy for malignant gliomas
Mol. Cancer Ther., July 1, 2007; 6(7): 1909 - 1919.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
M. Failly, S. Korur, V. Egler, J.-L. Boulay, M. M. Lino, R. Imber, and A. Merlo
Combination of sublethal concentrations of epidermal growth factor receptor inhibitor and microtubule stabilizer induces apoptosis of glioblastoma cells
Mol. Cancer Ther., February 1, 2007; 6(2): 773 - 781.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
I. K. Mellinghoff, T. F. Cloughesy, and P. S. Mischel
PTEN-Mediated Resistance to Epidermal Growth Factor Receptor Kinase Inhibitors
Clin. Cancer Res., January 15, 2007; 13(2): 378 - 381.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. A. Reardon, J. N. Rich, H. S. Friedman, and D. D. Bigner
Recent Advances in the Treatment of Malignant Astrocytoma
J. Clin. Oncol., March 10, 2006; 24(8): 1253 - 1265.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
D. A. Reardon and P. Y. Wen
Therapeutic advances in the treatment of glioblastoma: rationale and potential role of targeted agents.
Oncologist, February 1, 2006; 11(2): 152 - 164.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
I. K. Mellinghoff, M. Y. Wang, I. Vivanco, D. A. Haas-Kogan, S. Zhu, E. Q. Dia, K. V. Lu, K. Yoshimoto, J. H.Y. Huang, D. J. Chute, et al.
Molecular Determinants of the Response of Glioblastomas to EGFR Kinase Inhibitors.
N. Engl. J. Med., November 10, 2005; 353(19): 2012 - 2024.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by AAN Enterprises, Inc.